Over 16 million people in America suffer from neuropathic pain. This pain stems from either nerve injury, disease states, or toxic insults. A study from the National Institutes of Health researched whether cannabinoids, like CBD, could be used to address this unmet need. The results are pretty remarkable.
In this double-blind, randomized, placebo-controlled, parallel group study, it was analyzed whether cannabinoids could help peripheral neuropathic pain (PNP) treatment. For 15 weeks, the group study was analyzed and investigated. Over 300 people with peripheral neuropathic pain. This pain was associated with allodynia because it poses a significant clinical challenge.
Of these 303 people, 128 were randomized to cannabinoids, and 118 to placebo, in addition to their current analgesic therapy. Not only was there a statistically significant treatment difference favoring cannabinoids, but there was also a reduction in mean PNP scores in both treatment groups. However, the reduction was greater in the ones taking cannabinoids. Additionally, sleep quality was measured and improved greatly in favor of the cannabinoid treatment.
The study concluded by saying that these findings demonstrate that, “in a meaningful proportion of otherwise treatment-resistant patients,” there was improvement in pain, sleep quality, and Subject Global Impression of Change (SGIC). It also noted that the cannabinoids were well tolerated with no new safety concerns identified.
So, although this was only a study of 300 people. It did appear that cannabinoids were effective in treating, or at least diminishing the neuropathic pain experienced by these people.
A different study, examined whether cannabinoids would suppress chronic inflammation and neuropathic pain. In short, again, it found that they do. It states that:
“The cannabinoids significantly potentiate glycine currents in dorsal horn neurons in rat spinal cord slices. The analgesic potency of 11 structurally similar cannabinoids is positively correlated with cannabinoid potentiation of the α3 GlyRs. In contrast, the cannabinoid analgesia is neither correlated with their binding affinity for CB1 and CB2 receptors. NMR analysis reveals a direct interaction between CBD and S296 in the third transmembrane domain of purified α3 GlyR. The cannabinoid-induced analgesic effect is absent in mice lacking the α3 GlyRs. Our findings suggest that the α3 GlyRs mediate glycinergic cannabinoid-induced suppression of chronic pain. These cannabinoids may represent a novel class of therapeutic agents for the treatment of chronic pain and other diseases involving GlyR dysfunction.”
That’s Natural products are considered to be full spectrum meaning they contain cannabinoids and terpenes from the whole plant. Every mammal has an endocannabinoid system, which is fueled by these cannabinoids and terpenes. The combination of these compounds help to provide what is known as the entourage effect. Here you can listen to Dr. David Allen explain how the endocannabinoid system contributes to how our immune system and nervous system function. By providing pure, potent, and trusted products, That’s Natural continues to strive to meet our customer’s needs – something we have been doing for twelve years! With 100% traceability of where our hemp comes from, you can be confident in what you are putting on, or in, your body. For more questions regarding our CBD products, please visit our Questions and Answers page.*THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION. THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE.